Nat Rev Clin Oncol. Acta Naturae. J Mammary Gland Biol Neoplasia.
Chin J Cancer Res. Onco Targets Ther. Cancer Discov. OncoTargets Ther.
View Article : Google Scholar. Ther Adv Med Oncol.
Genes Dev. Trends Cell Biol. Nat Rev Cancer.
Nat Med. J Pharmacol Pharmacother.
N Engl J Med. Cancer Metastasis Rev. Chem Biol. Front Oncol. Acta Biochim Biophys Sin Shanghai.
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers
NPJ Breast Cancer. Regulating cell growth by modulating the expression of specific target genes, aberrant STAT activation is also strongly suspected in cancer. STAT oncogenic transcriptional roles include cell progression, differentiation, suppression of anti-tumor immunity, and promotion of survival through anti-apoptotic effects.
Constitutive STAT activity is especially noted in colorectal, myeloma, pancreatic, ovarian, liver, breast, prostate, lung, several forms of leukemia and lymphoma, in addition to other solid and hematological cancers. Agents which inhibit JAK2, a kinase phosphorylating STAT3, suppress growth, decrease invasion of carcinoma cells, and induce apoptosis.
Mutations in JAK2 can lead to leukaemia and lymphoma. For instance, to treat some forms of leukaemia, targeting and inhibiting JAKs could eliminate the effects of EPO signalling and perhaps prevent the development of leukaemia. From Wikipedia, the free encyclopedia. Journal of Biological Chemistry. Cell Communication and Signaling. Growth Factors.
Proceedings of the National Academy of Sciences. Cellular Signalling.
Molecular and Cellular Biology. Nature Cell Biology.
STAT inhibitors for cancer therapy.
Journal of Cell Science. Cancer Research. Nature Chemical Biology. Cell Research. Stem Cells.
Nature Reviews Immunology. Frontiers in Bioscience.
Scott, Latanya; R. Lawrence, Harshani; M. Sebti, Said; J. Lawrence, Nicholas; Wu, Jie Current Pharmaceutical Design.
Experimental Hematology. British Journal of Haematology.